Videos

Treatment of Refractory Metastatic Renal Cell Carcinoma

John L. Marshall, MD, chief of the  Division of Hematology/Oncology at Medstar Georgetown University Hospital, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the use of chemotherapy in patients with colorectal or other gastrointestinal cancers. He also highlights the importance of understanding each individual patient’s needs before making a treatment decision. 

Keith T. Flaherty, MD, professor of Medicine, Harvard Medical School, director of Clinical Research, Massachusetts General Hospital, discusses the rationale for combining agents like dabrafenib with trametinib or binimetinib with encorafenib for patients with melanoma.<br /> &nbsp;

David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, explains the significance of the initial results from a recent phase 1B/2 trial combining APR-246 and azacitidine (Vidaza) in patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.

Julie M. Vose, MD, MBA, Chief in the Division of Oncology/Hematology at the University of Nebraska Medical Center, discusses strategies for overcoming resistance in lymphoma during the 2018 Pan Pacific Lymphoma Conference.&nbsp;

Targeted Treatment for IDH2-Mutated AML

Kevin Kalinsky, MD, MS, assistant professor of medicine at Columbia University, discusses the results from a trial in HER2-positive breast cancer that was presented at the 2017 San Antonio Breast Cancer Symposium. The study looked at the use of trastuzumab (Herceptin) in combination with a checkpoint inhibitor in patients that were either PD-L1-positive or negative.

Diane Simeone, MD, director of the Pancreatic Cancer Center and associate director of Translational Research at NYU Langone&rsquo;s Perlmutter Cancer Center, discusses the current state of the pancreatic cancer treatment paradigm. She says it is a very exciting time for this field as there is a large body of researchers now involved.

Brad S. Kahl, MD, professor in the department of medicine at Washington School of Medicine at Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in older patients with mantle cell lymphoma. This agent is currently being investigated in the frontline setting for patients not eligible for stem cell transplant.

Sagar Lonial, MD, professor and chair, Department of Hematology &amp; Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the results from 2 large phase III trials presented earlier this year for triplet regimens including pomalidomide in multiple myeloma.

Jed A. Katzel, MD, medical oncologist at Kaiser Permanente Santa Clara, discusses the findings from a study using a generalized competing event model to look at patients with head and neck cancer.&nbsp;

Roy S. Herbst, MD, PhD, Yale Cancer Center, discusses the use of combination immunotherapy for the treatment of lung cancer.&nbsp;